Who are alcaftadine 0.25% ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone/Azelastine nasal spray, Morphine-Promethazine, Benadryl demand, Olopatadine Nasal Spray, olopatadine (OLO), diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alcaftadine-0-25-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

alcaftadine 0.25% ophthalmic solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

alcaftadine 0.25% ophthalmic solution (alcaftadine 0.25% ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective H1-receptor antagonist. Area: Ophthalmology.

marketed Selective H1-receptor antagonist H1 histamine receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

alcaftadine 0.25% ophthalmic solution (alcaftadine 0.25% ophthalmic solution) — Allergan. Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
alcaftadine 0.25% ophthalmic solution TARGET	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Benadryl demand	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
olopatadine (OLO)	olopatadine (OLO)	University of Chicago	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective H1-receptor antagonist class)

Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). alcaftadine 0.25% ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/alcaftadine-0-25-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab